PET-TC in Thyroid Evaluation

Last updated: February 26, 2025
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Overall Status: Active - Enrolling

Phase

N/A

Condition

Parathyroid Disease

Parathyroid Disorders

Parathyroid Cancer

Treatment

clinical practice drug treatment

Clinical Study ID

NCT06852144
PEPATI-MN-2024
322/2024/Oss/AOUBo
  • Ages > 18
  • All Genders

Study Summary

The thyroid gland may have a diffuse or focal uptake of numerous PET/CT radiopharmaceuticals and this may be correlated with underlying benign and malignant thyroid/parathyroid pathologies.

It is not clear at present if the uptake of the radiopharmaceutical alone is associated with a potential malignancy of the disease.

The aim of the study is to collect evidence and consolidate the diagnostic power of PET/CT, to identify any predictive parameters that can determine whether PET positivity/negativity can in the future avoid unnecessary tests such as needle aspiration.

Eligibility Criteria

Inclusion

Inclusion Criteria:

For the retrospective part:

  • Patients aged >18 years,

  • Findings of hypercaptant of thyroid/parathyroid relevance to PET/CT or known thyroidor parathyroid pathology and subsequent execution of PET/CT according to normalclinical practice,

  • Patients with cytological examination derived from needle aspiration performed nomore than 12 months time apart from PET/CT.

  • Obtaining informed consent

For the prospective part:

  • Patients aged >18 years,

  • Finding hypercaptant findings of thyroid/parathyroid relevance to PET/CT or knownthyroid or parathyroid pathology and subsequent execution of PET/CT according tonormal clinical practice.

  • Patients scheduled for agesult to be no more than 12 months.

  • Obtaining informed consent

Exclusion

Exclusion Criteria:

  • Nothing

Study Design

Total Participants: 418
Treatment Group(s): 1
Primary Treatment: clinical practice drug treatment
Phase:
Study Start date:
October 14, 2024
Estimated Completion Date:
April 30, 2029

Study Description

The primary objective of the study is to measure the diagnostic performance of PET/CT (with tracers used in our Center for Nuclear Medicine by normal clinical practice), in the identification of malignancy of thyroid or parathyroid findings, compared to cytological/histological examination in patients with known thyroid and/or parathyroid disease or in patients with incidental findings. The secondary objective is to find functional parameters and predictive imaging of malignancy/benign and risk class of the lesion.

Connect with a study center

  • Nuclear medicine, IRCCS, Azienda Ospedalierio-Universitaria di Bologna

    Bologna, Bo 38050
    Italy

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.